Ownership
Private
Employees
~50
Stage
Phase 1
Modalities
Protein therapeutics

Medannex General Information

Phase 1b clinical study ongoing in cancer patients, with parallel preparation for clinical studies in autoimmune diseases. Pre-clinical data demonstrates MDX-124 effectively blocks annexin-A1 action.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Edinburgh, Scotland
United Kingdom

Drug Pipeline

MDX-124
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Medannex's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Medannex Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Medannex's complete valuation and funding history, request access »

Medannex Investors

Morningside Ventures
Investor Type: Venture Capital
Holding: Minority
The Scottish Investment Bank (SIB)
Investor Type: Venture Capital
Holding: Minority